CONTENTS

List of Abbreviations I-III
List of Figures IV-X
List of Tables XI
ABSTRACT 1-7
AIMS AND OBJECTIVES 8-10

CHAPTER ONE
Review of Literature 11-53

Part I: Cancer, Chemotherapy and Unsaturated fatty acids 11-25
Hallmarks of cancer 12-13
Causes of cancer 13-14
Types of cancer 14-15
Classification of tumors 15-16
Prevention 16-17
Chemotherapy 18-21
Chemotherapy using natural compounds 18-19
Chemotherapy using synthetic drugs 19-21
Chemotherapy using mono- or poly- unsaturated fatty acids 21
Fatty acids 22
Polyunsaturated fatty acids (PUFA) 23-25
Sources of PUFA 23
PUFA effects on cell proliferation and signal transduction 23-24
Clinical studies 25
PUFAs, Oxidative Stress, and Cancer Therapies 25

Part II: Nanoparticles 26-53
Nanotechnology 26-27
Emerging nanoparticle therapeutics 27-29
Passive and active targeting using nanoparticles 30-31
Types of nanoparticles 31-36
Characteristics of nanoparticles 36-38
Liposomes 38-40
Different types of liposomes from different sources 40-43
  Fusogenic liposomes 40
  Escheriosomes 40-41
  Virosomes 41
  Archaeosomes 41-42
  Yeast lipid liposomes 42-43
Niosomes 43-45
Microspheres 45-46
Immune Stimulating Complex (ISCOMs) 46-47
siRNA Nanoparticles 48-50
Applications of nanoparticulate delivery systems 50-53
  Tumor targeting using nanoparticulate delivery systems 50-52
  Nanoparticles for oral delivery of peptides and proteins 52
  Targeting of nanoparticles to epithelial cells in the GI tract using ligands 52
  Nanoparticles for gene delivery 52-53
Conclusions 53

CHAPTER TWO
Synthesis and characterization of novel anticancer compounds 54-106
Introduction 54-59
Materials and Methods 59-61
Results 61-103
Discussions 104-106

CHAPTER THREE
Anticancer potential of novel propofol-FA analogues 107-133
Introduction 107-109
Materials and Methods 109-111
Results 112-130
Discussions 131-133
CHAPTER FOUR
Exploiting propofol-FA analogues bearing nanoparticles in tumor targeting

Introduction 134-138
Materials and Methods 138-147
Results 147-181
Discussions 182-186

CHAPTER FIVE
Anticancer efficacy of EC-siRNA nanoparticles on hepatocarcinoma

Introduction 187-191
Materials and Methods 191-197
Results 197-206
Discussions 207-211

CONCLUSIONS 212-214
BIBLIOGRAPHY 215-232